PharmaShots | Incisive News in 3 Shots

Subscribe Now

Vyjuvek

Krystal Biotech Reports EMA’s Validation of Vyjuvek for MAA to Treat Dystrophic Epidermolysis Bullosa (DEB)

Krystal Biotech Reports EMA’s Validation of Vyjuvek for MAA to Treat Dystrophic Epidermolysis Bullosa (DEB)

November 27, 2023

Krystal Biotech’s Vyjuvek (beremagene geperpavec) Receives the US FDA’s Approval for Dystrophic Epidermolysis Bullosa in Patients Aged ≥6 Months

Krystal Biotech’s Vyjuvek (beremagene geperpavec) Receives the US FDA’s Approval for Dystrophic Epidermolysis Bullosa in Patients...

May 22, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us